Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 5/20 | 0.52 |
| ▸ | LTA4H | P09960 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | TRHR | P34981 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11060360 | 0.92 | LTA4H (0.61) | ACEACE2LTA4HTSHR | |
| SCHEMBL30165330 | 0.88 | ACE (0.57) | ACEACE2LTA4HTSHR | |
| Oxalic Acid SCHEMBL11058316 | 0.88 | ACE (0.50) | ACEOPRM1ACE2 | |
| SCHEMBL9508358 | 0.86 | ACE (0.51) | ACEOPRM1ACE2LTA4HTSHR | |
| SCHEMBL20375824 | 0.86 | ACE (0.59) | ACEOPRM1ACE2 | |
| SCHEMBL9508348 | 0.86 | ACE (0.59) | ACEOPRM1ACE2 | |
| SCHEMBL8250626 | 0.86 | OPRM1 (0.60) | ACEOPRM1 | |
| SCHEMBL9551626 | 0.86 | ACE (0.66) | ACEACE2TSHR | |
| SCHEMBL9509731 | 0.86 | ACE (0.66) | ACEACE2TSHR | |
| SCHEMBL5030487 | 0.85 | ACE (0.54) | ACEOPRM1ACE2LTA4HTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1359934-B1 | TRIPEPTIDES AND TRIPEPTIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NEUROTELL AG (CH) | 2006-11-08 | — | — | EP | claimed |
| US-7129213-B2 | Tripeptides and tripeptide derivatives for the treatment of neurodegenerative diseases | NEUROTELL AG (CH) | 2006-10-31 | — | — | US | claimed |
| US-7122524-B2 | Tripeptides and tripeptide derivatives for the treatment of postlesional disease of the nervous system | NEUROTELL AG (CH) | 2006-10-17 | — | — | US | claimed |
| US-20050101538-A1 | Tripeptides and tripeptide derivatives for the treatment of neurodegenerative diseases | NEUROTELL AG (CH) | 2005-05-12 | — | — | US | claimed |
| US-20050080016-A1 | Tripeptides and tripeptide derivatives for the treatment of postlesional diseases of the nervous system | NEUROTELL AG (CH) | 2005-04-14 | — | — | US | claimed |
| EP-1363656-B1 | TRIPEPTIDES AND TRIPEPTIDE DERIVATIVES FOR THE TREATMENT OF POSTLESIONAL DISEASES OF THE NERVOUS SYSTEM | NEUROTELL AG (CH) | 2004-12-22 | — | — | EP | claimed |
| EP-1359934-B1 | TRIPEPTIDES AND TRIPEPTIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NEUROTELL AG (CH) | 2006-11-08 | — | — | EP | disclosed |
| US-7129213-B2 | Tripeptides and tripeptide derivatives for the treatment of neurodegenerative diseases | NEUROTELL AG (CH) | 2006-10-31 | — | — | US | disclosed |
| US-7122524-B2 | Tripeptides and tripeptide derivatives for the treatment of postlesional disease of the nervous system | NEUROTELL AG (CH) | 2006-10-17 | — | — | US | disclosed |
| US-20050101538-A1 | Tripeptides and tripeptide derivatives for the treatment of neurodegenerative diseases | NEUROTELL AG (CH) | 2005-05-12 | — | — | US | disclosed |
| US-20050080016-A1 | Tripeptides and tripeptide derivatives for the treatment of postlesional diseases of the nervous system | NEUROTELL AG (CH) | 2005-04-14 | — | — | US | disclosed |
| EP-1363656-B1 | TRIPEPTIDES AND TRIPEPTIDE DERIVATIVES FOR THE TREATMENT OF POSTLESIONAL DISEASES OF THE NERVOUS SYSTEM | NEUROTELL AG (CH) | 2004-12-22 | — | — | EP | disclosed |
| EP-1363656-A2 | TRIPEPTIDES AND TRIPEPTIDE DERIVATIVES FOR THE TREATMENT OF POSTLESIONAL DISEASES OF THE NERVOUS SYSTEM | Neurotell AG (CH) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002062373-A2 | TRIPEPTIDES AND TRIPEPTIDE DERIVATIVES FOR THE TREATMENT OF POSTLESIONAL DISEASES OF THE NERVOUS SYSTEM | NEUROTELL AG (CH) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101538-A1 | Tripeptides and tripeptide derivatives for the treatment of neurodegenerative diseases | HTT, ARGLU1, SLC1A5 | ACE 994/4885OPRM1 812/4885ACE2 1055/4885 |
| US-20050080016-A1 | Tripeptides and tripeptide derivatives for the treatment of postlesional diseases of the nervous system | NPY5R, VIP, ARGLU1 | ACE 599/4885OPRM1 810/4885ACE2 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.